NLC
VC Fund
Amsterdam, The Netherlands
NLC is a VC fund in Amsterdam focused on Health Care and Medical Device. NLC is the European health tech venture builder, bringing science-based health tech inventions to life. NLC's approach allows them to find inventions, and create and support ventures that have the potential to reach the patient. NLC was founded in 2014 by its CEO and founder Bert-Arjan Millenaar.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 73%
- Fund size:
- $15M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries NLC invests in
Stages NLC invests in
Countries NLC invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anne M. K. Reijns
|
|||
Bert-Arjan Millenaar
|
|||
Michiel Mussies
|
|||
Jola Danaj
|
|||
Sjaak Deckers
|
Investment Focus
Industry
- Health Care 30 (67%)
- Medical Device 26 (58%)
- Medical 24 (53%)
- Health Diagnostics 11 (24%)
- Artificial Intelligence 5 (11%)
Stage
- Pre-Seed 33 (73%)
- Seed 4 (9%)
- Venture - Series Unknown 3 (7%)
- Series A 1 (2%)
- Funding Round 1 (2%)
Country
- The Netherlands 31 (69%)
- Austria 2 (4%)
- United Kingdom 2 (4%)
- Italy 1 (2%)
- Ireland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anne M. K. Reijns
Lead Tech Partnerships
|
Lead Tech Partnerships | Total investments: 0 | Find email | |
|
Bert-Arjan Millenaar
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email | |
|
Michiel Mussies
Lead Venture Support
|
Lead Venture Support | Total investments: 0 | Find email | |
|
Jola Danaj
Investment Associate
|
Investment Associate | Total investments: 1 | Find email | |
|
Sjaak Deckers
Advisor
|
Advisor | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Respiosa
|
A simple, min-imally invasive surgically implanted solution to provide optimal therapy for tongue-based OSA. Respiosa prevents the tongue from collapsing into the airway when patients sleep on their backs. Designed and tested by world-class developers with ENT surgeons, the novel Respiosa implant system promises to deliver effective, durable andadjustable therapy. | $664.7K / Seed / Dec 03, 2025 | |
Ansana
|
Ansana develops sterilization solutions for the pharmaceutical and healthcare industries. This technology is significantly cutting patient risk, reducing the environmental imprint, lowering expenses, and increasing flow. | $1.8M / Seed / Sep 29, 2025 | |
Amotio
|
Amotio Health is a medical technology start-up focused on innovation in orthopaedic revision surgery, specifically targeting the safe and effective removal of orthopaedic bone cement during surgery. The company offers a personalised approach to these procedures, aiming to optimise patient outcomes and reduce surgical complexity. Amotio Health isalso involved in developing 3D-printed, patient-specific implants, which are designed to help patients regain mobility more quickly and with fewer complications. | $1.1M / Pre-Seed / Jul 03, 2025 | |
|
Amotio
|
Amotio Health is a medical technology start-up focused on innovation in orthopaedic revision surgery, specifically targeting the safe and effective removal of orthopaedic bone cement during surgery. The company offers a personalised approach to these procedures, aiming to optimise patient outcomes and reduce surgical complexity. Amotio Health isalso involved in developing 3D-printed, patient-specific implants, which are designed to help patients regain mobility more quickly and with fewer complications. | $1.1M / Pre-Seed / Jul 03, 2025 | |
Kaminari Medical
|
Kaminari Medical is developing a catheter that combines intravascular ultrasound (IVUS) and photoacoustic (PA) imaging in one catheter (IVPA). The Kaminari catheter can be used for more accurate stent placing and therapy guidance by providing better information on both plaque composition and location. | $2.5M / Oct 14, 2024 | |
StarTric
|
StarTric developes and is taken to clinical use as a transcatheter structural heart implantable device. They are developing a unique transcatheter repair implantable device to treat TR. They manage entrance to the right atrium, reducing the flow to the lungs. They offer heart failure, atrial fibrillation, and other morbidities. | Seed / Jul 08, 2024 | |
SERDA therapeutics
|
SERDA Therapeutics develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers such as pressure ulcers, open leg wounds, and diabetic foot ulcers. | $2.2M / Seed / Jun 03, 2024 | |
Altach Biomedical
|
Altach Biomedical is an NLC venture firm. It builds a portfolio of biomimetic cartilage grafts, enabling surgeons to repair cartilage abnormalities and improve patients' quality of life. | $1.3M / Equity Crowdfunding / May 22, 2024 | |
MindAffect
|
MindAffect is a company that uses artificial intelligence and neuroscience to improve neural circuit testing and human communication. The company's innovative BCI/AI algorithms read EEG and EMG signals at a faster and more accurate rate, allowing correct assessment of the validity of this pathway for all patient groups. | $1.2M / Series A / Apr 29, 2024 | |
Scinvivo
|
Scinvivo develops imaging technology that specializes in optical biopsy for bladder cancer diagnostics. | $5.1M / Venture - Series Unknown / Feb 21, 2024 | |
| See all 45 investments → | |||
Co-Investors
Development Bank of Wales
2 deals together
NV Industriebank LIOF
2 deals together
Orthopaedic Research UK
2 deals together
BGO Ventures
1 deal together
Brightlands Life Sciences Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does NLC invest in?
NLC invests primarily in Health Care, Medical Device and Medical startups, most often at Pre-Seed and Seed stage. Most of the 45 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NLC?
Public channels for NLC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NLC?
The team at NLC includes Anne M. K. Reijns (Lead Tech Partnerships), Bert-Arjan Millenaar (Founder & CEO) and Michiel Mussies (Lead Venture Support). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
